Tirzepatide vs semaglutide: the head-to-head data, side by side

TLDR. Tirzepatide (the molecule in Zepbound and Mounjaro) outperforms semaglutide (the molecule in Wegovy and Ozempic) on weight loss and A1C reduction in direct and indirect comparisons. Side-effect profiles overlap heavily, with modestly higher GI side effects on tirzepatide at high doses. Semaglutide has more completed phase 3 outcomes data (SELECT cardiovascular, FLOW kidney). Tirzepatide has the OSA approval, the HFpEF approval, and stronger phase 2 MASH data. Insurance treats them similarly for obesity, somewhat differently for indication-specific coverage. The right molecule depends on the comorbidity profile, not on which one is theoretically stronger.

The two molecules

Semaglutide is a GLP-1 receptor agonist. Approved as Ozempic (T2D), Wegovy (obesity, cardiovascular event reduction), and Rybelsus (oral semaglutide for T2D). Once-weekly injectable. Approved doses for obesity: 0.25, 0.5, 1.0, 1.7, 2.4 mg.

Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Approved as Mounjaro (T2D) and Zepbound (obesity, OSA, HFpEF). Once-weekly injectable. Approved doses: 2.5, 5, 7.5, 10, 12.5, 15 mg.

The mechanistic difference matters. GIP is a second incretin hormone that complements GLP-1 in glucose regulation and may contribute to weight loss through additional pathways including adipose-tissue effects. Tirzepatide's dual mechanism is the likely explanation for its superior efficacy on weight and A1C, although the question is still being studied.

SURPASS-2: head-to-head in T2D

SURPASS-2 was the only direct head-to-head trial of tirzepatide versus semaglutide in T2D. 1,879 adults with T2D inadequately controlled on metformin, randomized to tirzepatide 5 mg, 10 mg, 15 mg, or semaglutide 1 mg weekly, for 40 weeks.

A1C reduction at 40 weeks:

• Semaglutide 1 mg: 1.86 percentage points
• Tirzepatide 5 mg: 2.01 points
• Tirzepatide 10 mg: 2.24 points
• Tirzepatide 15 mg: 2.30 points

Body weight reduction at 40 weeks:

• Semaglutide 1 mg: 5.7 kg (6.2 percent)
• Tirzepatide 5 mg: 7.6 kg (8.5 percent)
• Tirzepatide 10 mg: 9.3 kg (10.7 percent)
• Tirzepatide 15 mg: 11.2 kg (12.4 percent)

The trial compared 1 mg semaglutide to up to 15 mg tirzepatide. The 1 mg dose is the maintenance dose for Ozempic, but semaglutide is also approved at 2.0 mg for T2D and 2.4 mg for obesity. SURPASS-2 did not include those higher doses, so the head-to-head comparison is not perfectly matched on dose ceiling.

SURMOUNT-1 versus STEP-1: indirect in obesity

No direct head-to-head trial has compared tirzepatide and semaglutide for obesity. The indirect comparison from the parallel obesity trials:

• STEP-1 (semaglutide 2.4 mg, 68 weeks): 14.9 percent body weight reduction versus 2.4 percent placebo.
• SURMOUNT-1 (tirzepatide 5 mg, 72 weeks): 15.0 percent reduction.
• SURMOUNT-1 (tirzepatide 10 mg): 19.5 percent reduction.
• SURMOUNT-1 (tirzepatide 15 mg): 20.9 percent reduction.

Indirect comparisons across separate trials are less reliable than direct head-to-head data. Patient populations, trial duration, and protocols differ. Conservatively: tirzepatide 5 mg is roughly equivalent to semaglutide 2.4 mg on weight loss, and tirzepatide at 10 mg and above is meaningfully more effective on weight reduction.

SURMOUNT-5: the second head-to-head

SURMOUNT-5 was the obesity-indication direct head-to-head, randomizing 751 adults with obesity (without T2D) to tirzepatide 10 to 15 mg or semaglutide 2.4 mg for 72 weeks. Results published in NEJM May 2025:

• Tirzepatide: 20.2 percent body weight reduction.
• Semaglutide: 13.7 percent.
• Absolute difference: 6.5 percentage points favoring tirzepatide.
• Tirzepatide superior on every prespecified weight-loss endpoint.
• GI side effects were similar between groups overall, with modest tilt toward more GI events on tirzepatide.

This is now the cleanest direct comparison in the obesity indication.

Side effect profiles compared

From the trial data:

The trial numbers run against the conventional assumption that tirzepatide is harder on patients. SURMOUNT-1 patients reported less nausea and lower discontinuation rates than STEP-1 patients on semaglutide, despite the larger weight loss. The trial titration schedules were not identical, which may explain some of the difference. Real-world experience varies, with some patients tolerating one molecule far better than the other.

Both molecules carry the same boxed warning for thyroid C-cell tumors based on rodent studies. Both have the same pancreatitis and gallbladder signals. Both require the same contraindications (personal or family history of medullary thyroid carcinoma, MEN2, pregnancy).

Outcomes data: where each molecule has the harder evidence

Semaglutide leads on:

• Cardiovascular outcomes: SELECT (20 percent MACE reduction in established CVD with overweight). No equivalent completed tirzepatide trial.
• Kidney outcomes: FLOW (24 percent major kidney event reduction in T2D with CKD). No equivalent completed tirzepatide trial.
• Decade-long real-world experience. Semaglutide has been on the market since 2017. Tirzepatide since 2022.
• MASH: ESSENCE phase 3 topline reported in 2024. Tirzepatide has only phase 2 SYNERGY-NASH so far.

Tirzepatide leads on:

• Obesity efficacy: SURMOUNT-5 head-to-head.
• T2D A1C: SURPASS-2 head-to-head.
• OSA: SURMOUNT-OSA, FDA-approved.
• HFpEF: SUMMIT, FDA-approved.
• MASH phase 2: Larger SYNERGY-NASH effect size than ESSENCE on a per-trial basis.

Insurance coverage differences

For obesity, commercial insurance covers both Wegovy and Zepbound under similar PA criteria. Patients with strong preferences usually get whichever they request, assuming the prescriber writes accordingly.

For Medicare:

• Wegovy is covered under the CV indication only. Patients with established CVD and BMI 27 or higher can access Wegovy.
• Zepbound is covered under the OSA indication and the HFpEF indication. Patients with moderate-to-severe OSA or HFpEF with obesity can access Zepbound.

The Medicare pattern means the choice of molecule often follows the qualifying indication rather than patient preference. A Medicare patient with CVD but not OSA has Wegovy. A Medicare patient with OSA but not CVD has Zepbound. A Medicare patient with both has a real choice.

For T2D, both Ozempic and Mounjaro are covered on most commercial and Medicare Part D plans. Many plans have a step therapy that requires one to be tried before the other. The required order varies by plan.

Cash-pay pricing compared

• NovoCare Wegovy self-pay: $499 per month with periodic promotional pricing.
• LillyDirect Zepbound vials: $349 to $499 per month depending on dose.
• NovoCare Ozempic self-pay: Typically not available; T2D patients pursue insurance.
• Mounjaro retail cash-pay: Around $1,069 per month at standard pharmacy without coverage.

For cash-pay obesity patients, Zepbound vials are usually the cheaper path. For cash-pay T2D patients, neither molecule is reasonable at retail; insurance is the path.

The honest patient case

For an obesity patient without comorbidities choosing between molecules:

• If maximum weight loss is the goal: tirzepatide.
• If decade-long real-world safety is the priority: semaglutide.
• If GI tolerance is uncertain: try semaglutide first; tirzepatide is reasonable backup if semaglutide is intolerable.
• If insurance prefers one: follow the coverage.

For a patient with cardiovascular disease: semaglutide (SELECT indication, Medicare access). For a patient with kidney disease: semaglutide (FLOW indication). For a patient with OSA: tirzepatide (SURMOUNT-OSA indication). For a patient with HFpEF: tirzepatide (SUMMIT indication).

For a patient with multiple of these comorbidities, the choice depends on which condition is more clinically pressing and which carries the cleaner coverage path.

The compounded versus branded dimension

Beyond the molecule comparison, the regulatory pathway differs:

• Compounded semaglutide. Was widely available 2023 to 2024. After the FDA shortage resolution in October 2024, the broad commercial path closed. Narrow medical-necessity carve-outs remain at some 503A pharmacies. The evidence base on compounded products is unclear because trials use branded formulations.
• Compounded tirzepatide. Followed a similar trajectory. FDA shortage resolution for tirzepatide closed the broad path in late 2024.
• Branded products. Wegovy, Ozempic, Mounjaro, Zepbound all remain available. Pricing has dropped through manufacturer self-pay programs (NovoCare, LillyDirect) but remains substantially higher than the prior compounded pricing.
• Generic semaglutide. Expected late 2026 to early 2027 in the US, contingent on ANDA approvals. Will likely reshape the cash-pay tier.
• Generic tirzepatide. Multiple years away. Tirzepatide's patent estate is more recent.

Patients comparing the two molecules in 2026 should factor regulatory trajectory into the decision. A patient choosing semaglutide today is entering a market that will likely have a cheap generic option within 12 to 18 months. A patient choosing tirzepatide is entering a market that will remain branded-only for several years.

The switching decision in practice

Patients commonly ask whether to switch from one to the other. The reasonable framework:

• Switch from semaglutide to tirzepatide when: weight loss has plateaued and additional reduction is desired, GI tolerability on semaglutide is poor and the patient has not yet tried tirzepatide, an OSA or HFpEF indication argues for tirzepatide, the patient is committed to long-term branded therapy and the head-to-head efficacy difference matters.
• Switch from tirzepatide to semaglutide when: cardiovascular or kidney disease emerges and the SELECT or FLOW indications matter, insurance coverage shifts to favor semaglutide, generic semaglutide arrives and the cost difference is meaningful, GI tolerability on tirzepatide is poor.
• Stay on the current molecule when: the patient is stable, the weight goal is being met, the comorbidity profile does not push toward the other product, insurance coverage is settled.

The dose-equivalence question

There is no formal dose-equivalence table between tirzepatide and semaglutide. Approximate clinical equivalence based on weight-loss effect:

• Tirzepatide 5 mg roughly equivalent to semaglutide 2.4 mg (about 15 percent body weight reduction).
• Tirzepatide 10 mg meaningfully more effective than semaglutide 2.4 mg.
• Tirzepatide 15 mg substantially more effective than semaglutide 2.4 mg.
• For A1C reduction, tirzepatide doses produce 0.2 to 0.5 percentage points more A1C reduction than semaglutide 1 mg at comparable steps.

These are population-level approximations. Individual response varies. When switching, restart the new molecule at its lowest dose regardless of the prior dose and titrate based on tolerance and response.

Frequently asked questions

Is tirzepatide always better than semaglutide?

For weight loss and A1C reduction in head-to-head trials, yes, by a meaningful margin. For overall clinical use, no. The semaglutide outcomes data (cardiovascular, kidney) gives that molecule indications that tirzepatide cannot yet match.

Can I switch from one to the other?

Yes. Switches are clinically routine. Most prescribers restart at the lowest dose of the new medication, regardless of the prior dose, then titrate. The transition takes 4 to 8 weeks to reach a maintenance dose comparable to the prior medication.

Are the side effects really that different?

The trial data suggests modestly less nausea and vomiting on tirzepatide despite the larger weight loss. Real-world experience varies. Many patients who could not tolerate semaglutide do well on tirzepatide; some find tirzepatide harder. There is no reliable predictor of individual tolerance for either molecule.

Will tirzepatide also reduce cardiovascular events?

Probably, but the trial that proves it (SURPASS-CVOT) has not yet reported. Most cardiologists treat the cardiovascular benefit as likely class-based, but Medicare coverage and FDA indications depend on completed trials with specific molecules.

What about oral versions?

Rybelsus (oral semaglutide) is approved for T2D, not obesity, and has lower bioavailability than the injectable. An oral tirzepatide formulation is in development but not yet approved. For most patients pursuing obesity treatment, the injectable is what the evidence and labels support.

For the broader Wegovy drug profile, see Wegovy. For Zepbound, see Zepbound. For the cardiovascular case, see Wegovy for cardiovascular secondary prevention. For the kidney case, see Ozempic for kidney disease. For the HFpEF case, see Zepbound for HFpEF. For the MASH case, see Zepbound for MASH. To check program rankings for each, see best for Wegovy and best for Zepbound.

Citations

• Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM 2021;385:503-515. nejm.org/doi/full/10.1056/NEJMoa2107519
• Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM 2025;392:2061-2071. nejm.org/doi/full/10.1056/NEJMoa2416394
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM 2021;384:989-1002. nejm.org/doi/full/10.1056/NEJMoa2032183
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205-216. nejm.org/doi/full/10.1056/NEJMoa2206038
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221-2232. nejm.org/doi/full/10.1056/NEJMoa2307563